에임드바이오

0009K0KOSDAQSector: Pharma & Biotech

₩19,460▼ 1.47%Market cap ₩1.26TAs of Jul 21, 2026 close · updated once daily

Grade A66.3 ptsTop 19% of 2,523 stocks

Financial strength

89.3

Price attractiveness

40.1

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

ⓘ Growth momentum not rated — will be included automatically as data accumulates

Financial strength

89.3

How much debt does it carry relative to equity?

Debt-to-equity ratio

3.3%

✓ Above median · Top 2.2% in sector

Sector median 51.5%

Can it cover what's due within a year?

Current ratio

3143.3%

✓ Above median · Top 2.2% in sector

Sector median 191.3%

How much of revenue becomes profit?

Operating margin

43.9%

✓ Above median · Top 1.9% in sector

Sector median -2.3%

How much did it earn on its own capital?

ROE (return on equity)

2.6%

✓ Above median · Top 36.4% in sector

Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

Price attractiveness

40.1

Is the price expensive relative to earnings?

P/E (price-to-earnings)

250.6x

✓ Above median · Top 40% in sector

Sector median P/E of profitable peers 14.4x · 57% loss-making

Is the price expensive relative to book value?

P/B (price-to-book)

6.54x

✗ Below median · Top 79.9% in sector

Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15